Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TELEFLEX INC M&A Activity 2016

Dec 2, 2016

30968_rns_2016-12-02_8cc7acd7-5fdb-4a5a-866f-880e2b216d8c.zip

M&A Activity

Open in viewer

Opens in your device viewer

8-K 1 a12-2x20168xkreprojectviol.htm 8-K html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Document created using Wdesk 1 Copyright 2016 Workiva Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) December 2, 2016

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

Delaware 1-5353 23-1147939
(State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (IRS Employer Identification No.)
550 East Swedesford Road, Suite 400, Wayne, Pennsylvania
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code (610) 225-6800
Not applicable
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On December 2, 2016, Teleflex Incorporated (the “Company”) issued a press release announcing that it had entered into a definitive agreement with Vascular Solutions, Inc. (“Vascular Solutions”), under which the Company will acquire Vascular Solutions (the “Acquisition”). A copy of the press release is furnished as Exhibit 99.1 hereto.

In connection with a conference call to be held by the Company on December 2, 2016 to discuss the Acquisition, representatives of the Company will present the slide presentation furnished as Exhibit 99.2 hereto. These slides are available on the Company’s investor relations website at www.teleflex.com/usa/investor/.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.3, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release, dated December 2, 2016

99.2 Conference Call Slide Presentation

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 2, 2016 TELEFLEX INCORPORATED By: /s/ Jake Elguicze Name: Jake Elguicze Title: Vice President, Investor Relations and Treasurer

EXHIBIT INDEX

Exhibit No. Description
99.1 Press Release, dated December 2, 2016
99.2 Conference Call Slide Presentation